Related Experiment Videos

[Malignant rheumatoid arthritis]

M Nobunaga1

  • 1Department of Clinical Immunology, Kyushu University.

Insights

Malignant rheumatoid arthritis (MRA), a severe form of rheumatoid arthritis (RA) with systemic vasculitis, affects 4-5% of RA patients. Advancements in treatment are improving prognosis for this condition.

Area of Science:

  • Rheumatology
  • Immunology
  • Pathology

Context:

  • Malignant rheumatoid arthritis (MRA) is a severe complication of rheumatoid arthritis (RA).
  • It involves systemic vasculitis or severe extra-articular manifestations, potentially leading to fatal outcomes.
  • MRA affects 4-5% of hospitalized RA patients, with a male to female ratio of 1:1.45.

Purpose:

  • To define and describe the characteristics of Malignant Rheumatoid Arthritis (MRA).
  • To outline the histological types, laboratory features, and epidemiological data of MRA.
  • To discuss the recent trends and prognosis of MRA.

Summary:

  • Histologically, rheumatoid vasculitis in MRA presents in three main types: RA type, PN type, and EA type.
  • Characteristic laboratory findings include high rheumatoid factor titers, immune complexes, hypocomplementemia, hypoproteinemia, decreased choline esterase, elevated alkaline phosphatase, and leukocytosis.
  • Recent observations suggest a decline in MRA incidence and improved prognosis, likely due to therapeutic advancements.

Impact:

  • Understanding MRA's distinct features aids in early diagnosis and management.
  • Improved prognosis highlights the effectiveness of contemporary RA treatments.
  • Further research into MRA pathogenesis can lead to targeted therapies.

Related Concept Videos